Age ≥ 18 years. 4. Have an acceptable organ function: o Albumin ≥ 2.5 g/dL. o Total Bilirubin < 3.0 × upper limit of normal (ULN) unless patient has Gilbert’s syndrome. o Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3.0 × ULN or ≤ 5 × ULN in the case of liver metastases. o Calculated or measured creatinine clearance > 35 mL/minute per the Cockcroft- Gault formula. o Absolute neutrophil count ≥ 1,500/mm 3. o Hemoglobin ≥ 9 g/dL. o Platelet count ≥ 100,000/mm3. 5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy of at least three m onths. 7. Patients, both females and males, of childbearing/reproductive potential must agree to use adequate contraception while included in the trial and for six months after the last treatment with HS -130 and/or HS -110. 8. Patients must be willing and have th e capacity to sign the informed consent form. 5.2 Exclusion Criteria Patient s MUST NOT enter the trial if they meet any of the following exclusion criteria : 1. Have clinically significant cardiac disease, including: o Onset of unstable angina within 6 months of signing the Informed Consent Form (ICF). o Acute myocardial infarction within 6 months of the signing the ICF. o Known congestive heart failure (Grade III or IV as classified by the New York Heart Association); and/ or a known decreased cardiac ejection fracti on (LVEF) of < 45%. o Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, despite optimal medical management. 2.